Breakthrough during recombinant interferon alfa therapy in patients with chronic Hepatitis C virus infection: Prevalence, etiology, and management

Hepatology

Volumn 21, Issue 3, 1995, Pages 645-649

  Roffi, Luigi ^a   Colloredo Mels, Guido ^b   Antonelli, Guido ^c   Bellati, Giorgio ^d   Panizzuti, Fabio ^a   Piperno, Alberto ^a   Pozzi, Massimo ^a   Ravizza, Davide ^a   Angeli, Giovanni ^b   Dianzani, Ferdinando ^e   Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b BOLOGNINI HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CHRONIC HEPATITIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIBODIES; CHRONIC DISEASE; FEMALE; HEPATITIS C; HUMAN; INTERFERON-ALPHA; MALE; MIDDLE AGE; PREVALENCE; RECOMBINANT PROTEINS; RECURRENCE; TREATMENT OUTCOME;

EID: 0028936256     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/0270-9139(95)90512-X     Document Type: Article

References (27)

1. Recombinant interferon alphatherapy for chronic hepatitis C: a randomized double-blind placebo-controlled trial
2. Resistance to recombinant interferon alpha-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies
3. Clinical significance of anti-IFN alpha antibodies titres during interferon therapy
4. The antiproliferative effect of lymphoblastoid interferon is not blocked by interferon alpha-2a neutralizing antibodies
5. The treatment of anti IFN alpha 2 antibody positive CML patients with natural interferon alpha
6. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
7. Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparations
8. Virus yield reduction assay for interferon by titration of Sindbis virus hemagglutinin
9. Importance of primers selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay
10. Prevalence of breakthrough in chronic hepatitis C during alpha interferon (aIFN) therapy
11. Autoantibodies to cytokines: friends or foes?
12. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alpha2a by intramuscolar injection
13. Anti-IFN alpha titres during interferon therapy
14. Why are there so many subtypes of alpha-interferon?
15. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon
16. Interferon antibodies may negate the antiviral effects of recombinant alpha interferon treatment in patients with chronic hepatitis B virus infection
17. Detection and incidence of neutralizing antibodies to interferon-Salpha-nl
18. Specificities of neutralizing antibodies during lymphoblastoid interferon rescue of patients with haematological disorders
19. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection
20. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase
21. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
22. HCV undergoes extensive mutational change in NS5 region in association with relapse/breakthrough following alpha-interferon therapy
23. Down regulation of interferon-stimulated gene expression by HIV and tumor necrosis factor
24. Changes in interferon receptors on peripheral blood mononuclear cell from patients with chronic hepatitis B being treated with interferon
25. Structure and function of the type I interferon receptor
26. Treatment of hairy cell leukemia with recombinant alpha interferon: in vivo down-regulation of alpha interferon receptors on tumor cells
27. Leucocyte derived interferon-alpha in patients with antibodies to recombinant interferon-alpha2b